izpis_h1_title_alt

Organoruthenium complexes with benzo-fused pyrithiones overcome platinum resistance in ovarian cancer cells
ID Kladnik, Jerneja (Author), ID Coverdale, James P. C. (Author), ID Kljun, Jakob (Author), ID Burmeister, Hilke (Author), ID Lippman, Petra (Author), ID Ellis, Francesca G. (Author), ID Jones, Alan M. (Author), ID Ott, Ingo (Author), ID Romero-Canelón, Isolda (Author), ID Turel, Iztok (Author)

.pdfPDF - Presentation file, Download (3,10 MB)
MD5: C069A57EB65F60B7C01CC82570AAF965
URLURL - Source URL, Visit https://www.mdpi.com/2072-6694/13/10/2493 This link opens in a new window

Abstract
Drug resistance to existing anticancer agents is a growing clinical concern, with many first line treatments showing poor efficacy in treatment plans of some cancers. Resistance to platinum agents, such as cisplatin, is particularly prevalent in the treatment of ovarian cancer, one of the most common cancers amongst women in the developing world. Therefore, there is an urgent need to develop next generation of anticancer agents which can overcome resistance to existing therapies. We report a new series of organoruthenium(II) complexes bearing structurally modified pyrithione ligands with extended aromatic scaffold, which overcome platinum and adriamycin resistance in human ovarian cancer cells. The mechanism of action of such complexes appears to be unique from that of cisplatin, involving G$_1$ cell cycle arrest without generation of cellular ROS, as is typically associated with similar ruthenium complexes. The complexes inhibit the enzyme thioredoxin reductase (TrxR) in a model system and reduce cell motility towards wound healing. Importantly, this work highlights further development in our understanding of the multi-targeting mechanism of action exhibited by transition metal complexes.

Language:English
Keywords:ruthenium, pyrithione, resistance to chemotherapy, cancer, ovarian, thioredoxin
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FKKT - Faculty of Chemistry and Chemical Technology
Publication status:Published
Publication version:Version of Record
Year:2021
Number of pages:21 str.
Numbering:Vol. 13, iss. 10, art. 2493
PID:20.500.12556/RUL-135447 This link opens in a new window
UDC:546.96:547.8:618.11-006
ISSN on article:2072-6694
DOI:10.3390/cancers13102493 This link opens in a new window
COBISS.SI-ID:64129539 This link opens in a new window
Publication date in RUL:15.03.2022
Views:996
Downloads:131
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Cancers
Shortened title:Cancers
Publisher:MDPI
ISSN:2072-6694
COBISS.SI-ID:517914137 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:20.05.2021

Secondary language

Language:Slovenian
Keywords:rutenij, organorutenijevi kompleksi, piritioni, rak jajčnikov

Projects

Funder:ARRS - Slovenian Research Agency
Funding programme:Young researchers

Funder:ARRS - Slovenian Research Agency
Project number:P1-0175
Name:Napredna anorganska kemija

Funder:ARRS - Slovenian Research Agency
Project number:BI-DE/17-19-3

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back